Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
VEGF inhibitor
Pharma
Clearside's CLS-AX excels in phase 2b trial, set for phase 3
Clearside’s CLS-AX has aced a phase 2b trial, achieving primary and secondary outcomes for patients with neovascular age-related macular degeneration.
Kevin Dunleavy
Oct 9, 2024 11:47am
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study
Sep 8, 2024 11:30am
Merck CMO talks Akeso, Summit's Keytruda head-to-head win
Jun 3, 2024 12:00pm
Appeals court backs Regeneron's antitrust suit against Novartis
Mar 19, 2024 10:40am
FDA rejects Outlook's Avastin reformulation for eye disease
Aug 30, 2023 11:30am
Eye drug Vabysmo blasts off as Roche's biggest growth driver
Apr 26, 2023 11:07am
